Shoulder Innovations (SI) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
10 Mar, 2026Market opportunity and industry trends
Global annual shoulder arthroplasty market estimated at $2.8B, with strong growth expected, especially in outpatient and ASC settings.
Shoulder pain is highly prevalent, affecting 1 in 5 people over 65 in the U.S., yet surgical treatments remain underutilized.
Shoulder arthroplasty is one of the fastest-growing MedTech segments, with U.S. procedures projected to reach ~250,000 in 2025.
Market is shifting toward reverse arthroplasty and inlay designs, now comprising over 70% of procedures.
Product innovation and clinical differentiation
InSet Glenoid implant addresses glenoid loosening, a major complication in shoulder arthroplasty, with data showing 100% implant survivorship and 87% reduction in "rocking horse" motion.
InSet technology supports both anatomic and reverse procedures, enabling seamless revision and conversion surgeries.
ProVoyance 3D platform uses AI/ML for patient-specific surgical planning, improving implant positioning and outcomes.
Instrument system reduces surgical tray usage from up to 9 to just 2, lowering costs and complexity, especially for ASCs.
Financial performance and growth drivers
Revenue reached $47.3M in 2025, with a 57% CAGR from 2023 to 2025 and gross margins of 76.5%.
1,976 implant systems sold in the latest period, up 62% year-over-year, with rapid surgeon adoption.
$124M in cash and equivalents as of the latest quarter.
Growth driven by new indications, higher ASPs, international expansion, and increased penetration among high-volume surgeons.
Latest events from Shoulder Innovations
- Strong Q2 growth and innovative, efficient solutions drive momentum in the shoulder arthroplasty market.SI
Morgan Stanley 23rd Annual Global Healthcare Conference8 Jul 2026 - Q4 revenue up 65% year-over-year; 2026 guidance targets 31–37% growth with strong margins.SI
Q4 20258 Jul 2026 - Director elections and auditor ratification approved; no stockholder questions submitted.SI
AGM 202626 Jun 2026 - Innovative implants and AI-driven planning fuel rapid growth in the $2.8B shoulder arthroplasty market.SI
Investor presentation10 Jun 2026 - Q1 2026 revenue surged 65% to $16.7M, with margin gains and a raised full-year outlook.SI
Q1 202613 May 2026 - Annual meeting to elect directors and ratify auditor, with strong governance and risk oversight.SI
Proxy filing29 Apr 2026 - Vote on director elections and auditor ratification at the June 26, 2026 annual meeting.SI
Proxy filing29 Apr 2026 - AI-driven innovation and outpatient focus fuel strong growth and new opportunities in shoulder arthroplasty.SI
2026 CG Musculoskeletal Conference4 Mar 2026 - Disruptive InSet Glenoid and AI-driven platform fuel rapid growth in shoulder arthroplasty.SI
Investor presentation3 Mar 2026